Advancements in Deep Learning for Early and Accurate Lung Cancer Detection: Trends and Future Prospects

Globally, lung cancer is a dominant mainspring of cancer-related death, and better patient outcomes depend on early identification. Lung cancer identification and classification from radiographic pictures is one area of medical image analysis where deep learning, and more specifically 2D Convolutional Neural Networks (CNNs), has illustrate significant potential. In addition to outlining a unique CNN architecture for precise and effective lung cancer diagnosis using chest radiographs, this study provides an investigation of the state-of-the-art in CNN-based techniques for lung cancer detection. Many convolutional layers with rectified linear unit (ReLU) activation functions make up the suggested 2D CNN architecture. Max-pooling layers are then used for feature extraction and down sampling. Each layer’s input is normalised via batch normalisation, which enhances the network’s generalisation and convergence. A sizable dataset of annotated chest radiographs is used to train the network, which teaches it to automatically identify pertinent characteristics suggestive of lung cancer. Utilising pretrained CNN models like VGG or ResNet that have been adjusted for better performance on the target dataset, transfer learning strategies are being investigated. This method enables the model to use insights from a bigger dataset, which is very helpful when working with sparsely annotated data. A variety of chest radiograph datasets are used in extended tests to assess the suggested 2D CNN architecture. To find the model’s performance, performance measures including accuracy, sensitivity, specificity, and area of the ROC curve (AUC) are premeditated. The findings show that the suggested 2D CNN design outperforms current techniques in precisely identifying lung cancer from chest radiographs. To sum up, the suggested 2D CNN-based method has a lot of promise for enhancing lung cancer early detection and diagnosis, which may result in better patient conclusion and lower death rates. To properly evaluate the therapeutic value and generalisability of the suggested strategy, additional investigation and validation on bigger and more varied datasets are necessary.